OSGIN1 Antibody

What is OSGIN1 and why is it important in cellular research?

OSGIN1 (also known as BDGI, OKL38) is a protein that regulates cellular differentiation and proliferation through the modulation of cell death pathways . It functions as an oxidative stress response protein that regulates apoptosis by inducing cytochrome c release from mitochondria . OSGIN1 is particularly significant in research because:

• It shows differential expression patterns in cancer versus normal tissues

• It responds to oxidative stress conditions, making it relevant for stress biology studies

• It has tumor-suppressive functions in certain contexts while promoting tumor progression in others

• Its expression is regulated by p53 and induced by DNA damage

The protein has three documented isoforms with molecular masses of 38, 52, and 61 kDa , which adds complexity to its detection and functional characterization.

What applications are OSGIN1 antibodies validated for?

OSGIN1 antibodies have been validated for multiple research applications, with varying degrees of effectiveness depending on the specific antibody:

When selecting an OSGIN1 antibody, researchers should verify the validation data for their specific species of interest and experimental application .

What species reactivity is available for OSGIN1 antibodies?

Current OSGIN1 antibodies show variable species reactivity:

When working with non-human models, it's critical to check the specific validation data or sequence homology predictions for the antibody of interest. Some antibodies may work in multiple species due to conserved epitopes, but experimental validation is always recommended .

How do I address the discrepancy between predicted (61 kDa) and observed molecular weights of OSGIN1 in Western blots?

The discrepancy between predicted and observed molecular weights of OSGIN1 reflects its multiple isoforms and potential post-translational modifications:

• Multiple isoforms: OSGIN1 has three documented isoforms with molecular masses of 38, 52, and 61 kDa . When performing Western blots, you may observe one or multiple bands depending on:

  • The specific antibody epitope and which isoforms it recognizes

  • The tissue or cell type being studied (isoform expression varies)

  • The experimental conditions (stress may induce different isoforms)

• Methodological approach to resolve isoforms:

  • Use gradient gels (4-20%) to better separate proteins in the 38-61 kDa range

  • Include positive controls with recombinant OSGIN1 of known isoforms

  • Compare results with isoform-specific RT-PCR to correlate protein bands with mRNA expression

  • Consider using isoform-specific antibodies if available

• Post-translational modifications: Modifications like phosphorylation may alter the observed molecular weight. For example, OSGIN1 enhances DYRK1A-mediated TUBB3 phosphorylation, suggesting it may itself be regulated by phosphorylation .

When reporting Western blot results, always clearly document which molecular weight bands were observed and considered to be specific OSGIN1 signals.

How does OSGIN1 function differ between cancer types, and what implications does this have for antibody-based detection methods?

OSGIN1 exhibits context-dependent functions across different cancer types, creating important considerations for antibody-based detection:

• Divergent roles in different cancers:

  • In non-small cell lung cancer (NSCLC): OSGIN1 is highly expressed and positively correlated with low survival rates and tumor size . It functions as a novel TUBB3 regulator promoting tumor progression and gefitinib resistance.

  • In ovarian cancer: OSGIN1 is downregulated compared to normal tissues and functions as a tumor suppressor . Loss of OSGIN1 promotes ovarian cancer growth and confers resistance to drug-induced ferroptosis.

• Implications for antibody-based detection:

  • Expression levels: Optimize antibody dilutions based on expected expression levels in your cancer type

  • Subcellular localization: OSGIN1 may localize differently (nuclear vs. cytoplasmic) depending on cancer type

  • Interacting partners: Consider co-immunoprecipitation experiments to detect cancer-specific protein complexes

• Methodological recommendations:

  • Use multiple antibodies targeting different epitopes to validate findings

  • Include positive and negative control tissues with known OSGIN1 expression patterns

  • Combine protein detection with functional assays to correlate expression with activity

What is the relationship between OSGIN1 and ferroptosis, and how can antibodies help investigate this connection?

The relationship between OSGIN1 and ferroptosis represents an emerging area of research with important implications:

• OSGIN1's role in ferroptosis regulation:

  • In ovarian cancer, OSGIN1 acts as a positive regulator of ferroptosis, with its loss conferring resistance to drug-induced ferroptosis

  • OSGIN1 knockdown decreases reactive oxygen species (ROS) levels, which are critical for ferroptosis execution

  • OSGIN1 appears to regulate ferroptosis through an AMPK-SLC2A3 axis in ovarian cancer

• Antibody-based experimental approaches:

  • Co-immunoprecipitation with anti-OSGIN1 antibodies to identify ferroptosis-related binding partners

  • Immunofluorescence to track OSGIN1 localization during ferroptosis induction

  • Western blot analysis to monitor OSGIN1 expression changes in response to ferroptosis inducers like erastin and sorafenib

  • Chromatin immunoprecipitation (ChIP) to identify transcriptional targets regulated by OSGIN1 during ferroptosis

• Combined experimental design:

This multifaceted approach would provide comprehensive insights into OSGIN1's contribution to ferroptosis sensitivity or resistance .

What are the optimal conditions for Western blot detection of OSGIN1?

Optimizing Western blot conditions for OSGIN1 detection requires attention to several technical factors:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors for cell/tissue lysis

  • For nuclear OSGIN1, consider nuclear extraction protocols

  • Avoid repeated freeze-thaw cycles of samples

• Gel electrophoresis parameters:

  • Use gradient gels (4-20%) to resolve multiple isoforms (38, 52, 61 kDa)

  • Load adequate protein (25-50 μg per lane) as demonstrated in validation data

  • Include positive controls such as A549 cells or transfected 293T cells

• Antibody parameters:

• Detection considerations:

  • For weak signals, consider enhanced chemiluminescence (ECL) substrates

  • Multiple bands may appear (38, 52, 61 kDa) representing different isoforms

  • The 52 kDa band is commonly observed in many cell types

• Troubleshooting common issues:

  • High background: Increase antibody dilution or use different blocking agent

  • No signal: Verify protein transfer, reduce antibody dilution, increase exposure time

  • Multiple unexpected bands: Use peptide competition or knockout/knockdown controls to verify specificity

Following validated protocols, such as those available from antibody manufacturers, can significantly improve detection outcomes .

How should I approach immunohistochemical detection of OSGIN1 in tissue samples?

Successful immunohistochemical detection of OSGIN1 in tissue samples requires careful protocol optimization:

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues: Use standard 10% formalin fixation for 24-48 hours

  • Fresh frozen tissues: Snap freeze immediately and prepare cryosections

  • Antigen retrieval: Use citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) with heat-induced epitope retrieval

• Staining protocol optimization:

  • Antibody dilution: Start with 1:100-1:200 or 5-20 μg/ml as recommended

  • Incubation: Overnight at 4°C for primary antibody

  • Detection system: HRP-conjugated secondary antibody with DAB or AEC chromogen

  • Counterstain: Hematoxylin for nuclear visualization

• Controls and validation:

  • Positive control: Include tissues known to express OSGIN1 (e.g., liver, ovary)

  • Negative control: Omit primary antibody or use isotype control

  • Antibody validation: Consider using multiple antibodies against different epitopes

  • Correlate with other detection methods (e.g., IF, WB) for confirmation

• Interpretation guidelines:

  • OSGIN1 may show both nuclear and cytoplasmic localization

  • Scoring systems should account for both staining intensity and percentage of positive cells

  • Quantification can be performed using digital pathology software (e.g., TissueFAXS)

• Special considerations for cancer tissues:

  • Expression levels vary by cancer type (high in NSCLC, low in ovarian cancer)

  • Compare tumor tissue with adjacent normal tissue in the same section when possible

  • Consider co-staining with proliferation markers or other relevant proteins to establish correlations

Following these methodological approaches will help ensure reliable and reproducible OSGIN1 detection in tissue samples .

What controls should be included when validating a new OSGIN1 antibody for research?

Rigorous validation of a new OSGIN1 antibody requires a comprehensive set of controls:

• Positive and negative expression controls:

  • Positive cell lines: A549 cells, transfected 293T cells overexpressing OSGIN1

  • Positive tissues: Human liver, ovary, and mouse/rat equivalents

  • Negative control: Cell lines with minimal OSGIN1 expression or non-transfected controls

• Genetic manipulation controls:

  • OSGIN1 overexpression: Transiently transfected cells with tagged OSGIN1 constructs

  • OSGIN1 knockdown/knockout: siRNA, shRNA, or CRISPR-Cas9 targeted cells

  • Rescue experiments: Re-expression in knockout backgrounds to confirm specificity

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide/protein

  • Compare staining patterns with and without peptide competition

  • Specific signal should be significantly reduced or eliminated

• Cross-reactivity assessment:

  • Test multiple species if cross-reactivity is claimed

  • Test in different tissue types to evaluate context-dependent specificity

  • Evaluate potential cross-reactivity with related proteins

• Validation across multiple applications:

• Orthogonal validation:

  • Correlation with mRNA expression data

  • Comparison of results across multiple antibodies targeting different epitopes

  • Mass spectrometry validation of immunoprecipitated proteins

This comprehensive validation approach ensures that experimental findings can be confidently attributed to OSGIN1 and not to non-specific interactions or artifacts .

How do I reconcile the contradictory findings regarding OSGIN1's role as both tumor suppressor and oncogene?

The seemingly contradictory roles of OSGIN1 in cancer reflect its context-dependent functions, which require careful experimental design and interpretation:

• Evidence for tumor suppressor function:

  • Downregulated in ovarian cancer tissues compared to normal ovaries

  • Overexpression inhibits ovarian cancer growth in vivo

  • Promotes ferroptosis, a type of cell death, in ovarian cancer models

  • Associated with regulation of apoptosis and stress responses

• Evidence for oncogenic function:

  • Highly expressed in NSCLC tissues and correlates with poor survival

  • Promotes gefitinib resistance in NSCLC

  • Enhances TUBB3 phosphorylation and promotes MKK3/6-p38 signaling pathway

• Reconciliation approaches:

  • Tissue-specific context: OSGIN1 may interact with different partners in different tissue types

  • Genetic background: Mutations in related pathways may determine whether OSGIN1 is pro- or anti-tumorigenic

  • Isoform specificity: Different isoforms (38, 52, 61 kDa) may have opposing functions

  • Stress conditions: OSGIN1's function may change under oxidative stress versus normal conditions

• Experimental design for addressing contradictions:

  • Use multiple cancer models to test OSGIN1 function

  • Analyze isoform-specific expression and function

  • Investigate subcellular localization in different contexts

  • Perform comprehensive protein interaction studies in different cancer types

  • Correlate with patient outcome data in specific cancer types

This context-dependent functionality highlights the importance of using multiple experimental approaches and cell/tissue models when studying OSGIN1 in cancer research .

How do post-translational modifications affect OSGIN1 detection by antibodies?

Post-translational modifications (PTMs) can significantly impact OSGIN1 detection by antibodies, creating important considerations for experimental design and data interpretation:

• Known and predicted PTMs of OSGIN1:

  • Phosphorylation: OSGIN1 enhances DYRK1A-mediated phosphorylation, suggesting it may itself be regulated by phosphorylation

  • Potential ubiquitination: As a regulated protein involved in stress responses

  • Potential SUMOylation: May affect nuclear localization

• Impact on antibody binding:

  • Epitope masking: PTMs may directly block antibody binding sites

  • Conformational changes: PTMs may alter protein folding, hiding or exposing epitopes

  • Cross-reactivity: Some antibodies may preferentially recognize modified forms

• Experimental strategies to address PTM effects:

• Interpretation guidelines:

  • Unexpected molecular weight shifts may indicate PTMs

  • Variable detection across different tissues/conditions may reflect different PTM states

  • Absence of signal doesn't necessarily mean absence of protein (could be modified form)

  • Consider using mass spectrometry to identify specific PTMs affecting detection

Understanding the relationship between PTMs and antibody detection is crucial for accurate interpretation of OSGIN1 expression data, particularly when comparing results across different experimental conditions or disease states .

How can I integrate OSGIN1 antibody data with transcriptomic findings when they show discordant results?

Reconciling discordant results between protein-level (antibody-based) and transcript-level data for OSGIN1 requires systematic analysis and integration:

• Common causes of protein-transcript discordance:

  • Post-transcriptional regulation: miRNAs or RNA-binding proteins affecting translation

  • Protein stability differences: Variations in protein half-life across conditions

  • Technical factors: Antibody specificity issues or RNA quality differences

  • Temporal dynamics: Time lag between transcription and translation

• Systematic analysis approach:

• Integration strategies:

  • Calculate protein-to-mRNA ratios across conditions to identify regulatory shifts

  • Use correlation analysis within specific contexts rather than expecting global correlation

  • Consider isoform-specific analysis at both protein and mRNA levels

  • Integrate with protein-protein interaction data to identify stabilizing partners

• Case study from literature:

  • In ovarian cancer, OSGIN1 mRNA levels were significantly lower in cancer tissues compared to normal tissues, consistent with protein-level findings

  • In NSCLC, both high mRNA and protein levels of OSGIN1 were associated with poor prognosis, showing concordance

  • When discordance occurs, consider context-specific regulation mechanisms

• Recommended validation experiments:

  • qRT-PCR for specific OSGIN1 isoforms alongside Western blot with isoform-resolving conditions

  • Polysome profiling to assess translation efficiency

  • Protein half-life measurements in relevant cell types

This integrated approach acknowledges that protein and transcript levels may legitimately differ due to biological regulation rather than technical artifacts .

How can OSGIN1 antibodies be used to study the role of this protein in ferroptosis pathways?

OSGIN1 antibodies provide valuable tools for investigating its emerging role in ferroptosis regulation:

• Experimental approaches for OSGIN1-ferroptosis studies:

  • Expression analysis: Monitor OSGIN1 levels during ferroptosis induction with erastin or sorafenib using Western blot

  • Subcellular tracking: Use immunofluorescence to track OSGIN1 localization changes during ferroptosis

  • Interaction mapping: Employ co-immunoprecipitation with anti-OSGIN1 antibodies to identify ferroptosis-related binding partners

  • Functional studies: Correlate OSGIN1 expression with lipid peroxidation and ROS levels

• Comprehensive experimental workflow:

• Specific applications in cancer research:

  • Comparative analysis of ferroptosis sensitivity in OSGIN1-high versus OSGIN1-low tumors

  • Identification of OSGIN1-dependent ferroptosis pathways using phosphoproteomics with OSGIN1 antibodies for immunoprecipitation

  • Development of OSGIN1 expression as a biomarker for ferroptosis-inducing therapy response

• Advanced combination approaches:

  • ChIP-seq with anti-OSGIN1 antibodies to identify transcriptional targets during ferroptosis

  • Proximity labeling combined with OSGIN1 antibodies to capture transient interactions during ferroptosis

  • OSGIN1 antibody-based tissue microarray analysis to correlate expression with ferroptosis markers in patient samples

This systematic approach leverages OSGIN1 antibodies to illuminate its role in ferroptosis, potentially leading to new therapeutic strategies targeting this pathway in cancer .

What are the considerations for using OSGIN1 antibodies in multiplexed imaging approaches?

Multiplexed imaging with OSGIN1 antibodies requires careful optimization to generate reliable, multi-parameter data:

• Optimal marker combinations with OSGIN1:

  • Cell type markers: Combine with epithelial/immune/stromal markers to identify OSGIN1+ cell populations

  • Functional markers: Pair with oxidative stress indicators (NRF2, SOD1) to correlate with OSGIN1 function

  • Pathway markers: Combine with AMPK, p38, TUBB3 to investigate signaling networks

  • Cell death markers: Pair with ferroptosis/apoptosis markers to correlate with cell fate

• Protocol optimization for OSGIN1 multiplexing:

  • Titrate antibodies individually before combining

  • Consider tyramide signal amplification for weak signals

  • Test fixation conditions that preserve all target epitopes

  • Determine optimal antibody order in sequential approaches

  • Validate multiplex results with single-stain controls

• Data analysis considerations:

  • Account for OSGIN1's multiple subcellular localizations in segmentation

  • Consider cellular heterogeneity in expression levels when setting thresholds

  • Correlate OSGIN1 with other markers at single-cell level for pathway analysis

These considerations enable researchers to effectively incorporate OSGIN1 antibodies into multiplexed imaging studies, providing rich contextual data about its expression and function in complex tissues .